Charles River Labs Plummets 17% On 'Bleaker' Expectations For 2024Investors Business Daily • 08/07/24
Charles River Laboratories (CRL) Surpasses Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/07/24
Unlocking Q2 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key MetricsZacks Investment Research • 08/05/24
Charles River Collaborates with Patient Advocacy Group, FOXG1 Research Foundation to Advance Rare Disease Gene Therapy DevelopmentBusiness Wire • 07/30/24
Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug DiscoveryBusiness Wire • 07/24/24
Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference CallBusiness Wire • 07/16/24
Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical CampusBusiness Wire • 06/25/24
Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell TherapyBusiness Wire • 06/17/24
Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research AlternativesBusiness Wire • 06/11/24
Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in SomervilleBusiness Wire • 06/06/24
Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in ResearchBusiness Wire • 06/04/24
Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy DevelopmentBusiness Wire • 05/30/24